Synonyms: SRF-617 | SRF617
Compound class:
Antibody
Comment: Perenostobart is a monoclonal antibody that targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1/CD39). Based on analysis using the amino acid (aa) sequences provided in the INN documentation and patented aa sequences (via NCBI Blast: protein), perenostobart would appear to map to Surface Oncology's clinical lead anti-CD39 mAb SRF617. Surface Oncology claim anti-CD39 mAbs in patent US10738128B2 [1]. SRF617 is a fully human mAb that was designed to inhibit the enzymatic activity of ENTPD1/CD39.
|
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
12269 | perenostobart |
Synonyms ![]() |
SRF-617 | SRF617 |
Database Links ![]() |
|
CAS Registry No. | 2643331-31-9 (source: WHO INN record) |
GtoPdb PubChem SID | 472319225 |
Search PubMed clinical trials | perenostobart |
Search PubMed titles | perenostobart |
Search PubMed titles/abstracts | perenostobart |